Innovative Product Launches Aviva Systems Biology has recently introduced new specialized reagents such as anti-progranulin recombinant monoclonal antibodies and the AvivaBlot ECL reagents, demonstrating their commitment to advancing research tools across neurodegeneration, inflammation, and diagnostic fields. These launches highlight opportunities to promote complementary products or co-develop tailored solutions with existing and emerging clients.

Customization Capabilities With their Protein on Demand semi-custom recombinant protein portfolio and custom antibody discovery services, Aviva offers tailored solutions for research institutions seeking specific reagents. This positions them well to meet the increasing demand for personalized research tools, presenting a sales opening in collaboration and contract research services.

Active Research Support Supporting high-impact areas such as neuroscience, cancer, and immunology, Aviva’s comprehensive catalog and recent product innovations indicate strong engagement with cutting-edge research. Targeting research labs working on biomarker development or translational assays could drive sales in reagents and assay development solutions.

Collaborative Opportunities Recent partnerships, including co-developing sample preparation kits, suggest openness to collaborations that can expand their product offerings. This creates potential business opportunities with biotech firms and academic institutions aiming to enhance their diagnostic or research workflows with integrated solutions.

Global Market Reach With distributors worldwide and headquarters in San Diego, Aviva has a strategic geographic presence supporting international research markets. Sales teams can leverage this global footprint to target research centers and biotech companies across different regions, emphasizing their capacity to provide region-specific support and products.